369 related articles for article (PubMed ID: 34025931)
1. CRISPR/Cas9 based genome editing for targeted transcriptional control in triple-negative breast cancer.
Deepak Singh D; Han I; Choi EH; Yadav DK
Comput Struct Biotechnol J; 2021; 19():2384-2397. PubMed ID: 34025931
[TBL] [Abstract][Full Text] [Related]
2. CRISPR/Cas9 as a therapeutic tool for triple negative breast cancer: from bench to clinics.
Tiwari PK; Ko TH; Dubey R; Chouhan M; Tsai LW; Singh HN; Chaubey KK; Dayal D; Chiang CW; Kumar S
Front Mol Biosci; 2023; 10():1214489. PubMed ID: 37469704
[TBL] [Abstract][Full Text] [Related]
3. Breast Cancer Transcriptional Regulatory Network Reprogramming by using the CRISPR/Cas9 System: An Oncogenetics Perspective.
Singh DD; Verma R; Tripathi SK; Sahu R; Trivedi P; Yadav DK
Curr Top Med Chem; 2021; 21(31):2800-2813. PubMed ID: 34477520
[TBL] [Abstract][Full Text] [Related]
4. CRISPR/Cas genome editing in triple negative breast cancer: Current situation and future directions.
Fu L; Li Z; Ren Y; Yu H; Liu B; Qiu Y
Biochem Pharmacol; 2023 Mar; 209():115449. PubMed ID: 36754153
[TBL] [Abstract][Full Text] [Related]
5. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
6. Current applications and future perspective of CRISPR/Cas9 gene editing in cancer.
Wang SW; Gao C; Zheng YM; Yi L; Lu JC; Huang XY; Cai JB; Zhang PF; Cui YH; Ke AW
Mol Cancer; 2022 Feb; 21(1):57. PubMed ID: 35189910
[TBL] [Abstract][Full Text] [Related]
7. Extending CRISPR-Cas9 Technology from Genome Editing to Transcriptional Engineering in the Genus Clostridium.
Bruder MR; Pyne ME; Moo-Young M; Chung DA; Chou CP
Appl Environ Microbiol; 2016 Oct; 82(20):6109-6119. PubMed ID: 27496775
[TBL] [Abstract][Full Text] [Related]
8. Comparative analysis of mouse and human preimplantation development following POU5F1 CRISPR/Cas9 targeting reveals interspecies differences.
Stamatiadis P; Boel A; Cosemans G; Popovic M; Bekaert B; Guggilla R; Tang M; De Sutter P; Van Nieuwerburgh F; Menten B; Stoop D; Chuva de Sousa Lopes SM; Coucke P; Heindryckx B
Hum Reprod; 2021 Apr; 36(5):1242-1252. PubMed ID: 33609360
[TBL] [Abstract][Full Text] [Related]
9. New Insights into the Therapeutic Applications of CRISPR/Cas9 Genome Editing in Breast Cancer.
Ahmed M; Daoud GH; Mohamed A; Harati R
Genes (Basel); 2021 May; 12(5):. PubMed ID: 34066014
[TBL] [Abstract][Full Text] [Related]
10. Modulating CRISPR/Cas9 genome-editing activity by small molecules.
Chen S; Chen D; Liu B; Haisma HJ
Drug Discov Today; 2022 Apr; 27(4):951-966. PubMed ID: 34823004
[TBL] [Abstract][Full Text] [Related]
11. Nanomaterial-assisted CRISPR gene-engineering - A hallmark for triple-negative breast cancer therapeutics advancement.
Farheen J; Hosmane NS; Zhao R; Zhao Q; Iqbal MZ; Kong X
Mater Today Bio; 2022 Dec; 16():100450. PubMed ID: 36267139
[TBL] [Abstract][Full Text] [Related]
12. Can genetic engineering-based methods for gene function identification be eclipsed by genome editing in plants? A comparison of methodologies.
Amritha PP; Shah JM
Mol Genet Genomics; 2021 May; 296(3):485-500. PubMed ID: 33751237
[TBL] [Abstract][Full Text] [Related]
13. Genome-editing approaches and applications: a brief review on CRISPR technology and its role in cancer.
Siva N; Gupta S; Gupta A; Shukla JN; Malik B; Shukla N
3 Biotech; 2021 Mar; 11(3):146. PubMed ID: 33732568
[TBL] [Abstract][Full Text] [Related]
14. CRISPR/Cas9 application in cancer therapy: a pioneering genome editing tool.
Shojaei Baghini S; Gardanova ZR; Abadi SAH; Zaman BA; İlhan A; Shomali N; Adili A; Moghaddar R; Yaseri AF
Cell Mol Biol Lett; 2022 May; 27(1):35. PubMed ID: 35508982
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic genome editing of triple-negative breast tumors using a noncationic and deformable nanolipogel.
Guo P; Yang J; Huang J; Auguste DT; Moses MA
Proc Natl Acad Sci U S A; 2019 Sep; 116(37):18295-18303. PubMed ID: 31451668
[TBL] [Abstract][Full Text] [Related]
16. Engineering nucleic acid chemistry for precise and controllable CRISPR/Cas9 genome editing.
Cai W; Wang M
Sci Bull (Beijing); 2019 Dec; 64(24):1841-1849. PubMed ID: 36659580
[TBL] [Abstract][Full Text] [Related]
17. CRISPR-Cas9, A Promising Therapeutic Tool for Cancer Therapy: A Review.
Akram F; Ikram Ul Haq ; Ahmed Z; Khan H; Ali MS
Protein Pept Lett; 2020; 27(10):931-944. PubMed ID: 32264803
[TBL] [Abstract][Full Text] [Related]
18. A glance at genome editing with CRISPR-Cas9 technology.
Barman A; Deb B; Chakraborty S
Curr Genet; 2020 Jun; 66(3):447-462. PubMed ID: 31691023
[TBL] [Abstract][Full Text] [Related]
19. Application of the CRISPR/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer.
Zhang H; Qin C; An C; Zheng X; Wen S; Chen W; Liu X; Lv Z; Yang P; Xu W; Gao W; Wu Y
Mol Cancer; 2021 Oct; 20(1):126. PubMed ID: 34598686
[TBL] [Abstract][Full Text] [Related]
20. Use of CRISPR/Cas9 gene-editing tools for developing models in drug discovery.
Ahmad G; Amiji M
Drug Discov Today; 2018 Mar; 23(3):519-533. PubMed ID: 29326075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
